What's the Difference Between RePL and ReOC? A Beginner's Guide to CASA Certifications
In this article, you will learn what each certification means, how they differ, and why they matter. It also offers some practical advice on which one might be right for you. CASA's Role in Regulating Drones in Australia
CASA, or the Civil Aviation Safety Authority, is the regulatory body overseeing all civil aviation activities in Australia. That includes drones, which are popular for everything from photography to inspections. CASA sets the rules to keep everyone safe, whether you're flying for fun or business.
For commercial drone operators, understanding CASA's regulations isn't only about compliance, it's about ensuring your operation is legal and safe. Knowing the difference between RePL and ReOC can seem confusing at first, but it's crucial to get it right before you take off. What is a Remote Pilot Licence (RePL)?
A RePL is like a driver's licence for drone pilots. It's a personal certification that allows you to operate drones commercially, those under 7kg or up to 25kg, depending on the specifics. If you're flying drones as part of your job or business, you'll need a RePL.
Getting a RePL involves training through CASA-approved providers like Ace Aviation. The process is straightforward and quicker than obtaining a ReOC. Once you're certified, you can work for various clients or companies, provided you stick to CASA's rules.
A ReOC is a certification for businesses or organisations that want to run drone operations. Think of it as an operating licence for a company rather than an individual. With a ReOC, you can employ RePL holders or manage multiple pilots, making it ideal for drone service companies or freelancers who want to scale up.
Applying for a ReOC is more involved. It requires a formal application, detailed operating manuals, procedures, and accountability systems. It's about demonstrating that your organisation can operate safely and responsibly at a larger scale. Key Differences Between RePL and ReOC RePL ReOC Personal certification Organisational certification Quicker to obtain Involves a formal application process Needed for individual pilots Needed for businesses or drone operations
A quick way to think about it: RePL is like your driver's licence, personal and quick to get. ReOC is like a business licence, more paperwork, more responsibility.
If you're flying drones for someone else's business, like a photographer working for a wedding company, a RePL is probably what you need. It's your ticket to legally operate drones commercially.
If you want to start your drone business, offering aerial inspections, surveying, or mapping, you'll need a ReOC. Many students at Ace Aviation start with a RePL and then, as they grow, move on to a ReOC through the Fast-Track program.
Getting your head around RePL vs ReOC is a crucial step in building a career or business in the drone industry. Both certifications serve different purposes but are equally important for compliant, safe operations.
If you're ready to take the next step, Ace Aviation offers CASA-certified RePL training that gets you flying legally and confidently. We also provide ReOC Fast-Track options for entrepreneurs eager to expand.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 hours ago
- Business Wire
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. 'We appreciate the continued support of our limited partners, many of whom have been with us since the launch of our first dedicated venture fund in 2016,' said Patrick Heron, Managing Partner at Frazier Life Sciences. 'With FLS XII, we look forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs with the potential to address significant medical needs.' Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds since 2016, alongside more than $1.7 billion raised in long-only public funds since 2021. The FLS team includes seven investment partners and a growing group of over 35 investment professionals, operating professionals, and senior advisors with broad biopharmaceutical experience across therapeutic areas and company stages. The firm takes a hands-on, collaborative approach to company building, leading to 25 new companies launched since 2020. Noteworthy investments include Alpine Immune Sciences (acquired by Vertex), Arcutis Biotherapeutics (NASDAQ: ARQT), Mirum Pharmaceuticals (NASDAQ: MIRM), NewAmsterdam Pharma (NASDAQ: NAMS), Tarsus Pharmaceuticals (NASDAQ: TARS), and Amunix Pharmaceuticals (acquired by Sanofi), among others. About Frazier Life Sciences Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved over 65 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions. FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle, and Boston. For more information, please visit and follow us on LinkedIn.
Business Wire
18 hours ago
- Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2025. Financial Results Total Revenue: For the three and six months ended June 30, 2025, total revenue was $70.0 million and $132.5 million, up 22% and 23%, respectively, from $57.2 million and $107.5 million, respectively, for the same periods of 2024. Net Product Sales: For the three and six months ended June 30, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $66.6 million and $126.5 million, up 21% and 23%, respectively, from $55.0 million and $103.1 million, respectively, for the same periods of 2024. License, Collaboration and Royalty Revenue: For the three and six months ended June 30, 2025, license, collaboration and royalty revenue, which includes manufacturing services revenue from Aurinia's collaboration partner, Otsuka, was $3.4 million and $5.9 million, up 55% and 34%, respectively, from $2.2 million and $4.4 million, respectively, in the same periods of 2024. Net Income (Loss): For the three and six months ended June 30, 2025, net income (loss) was $21.5 million and $44.9 million, respectively, compared to $0.7 million and $(10.0) million, respectively, in the same periods of 2024. Cash Flow Provided by (Used in) Operating Activities: For the six months ended June 30, 2025, cash flow provided by (used in) operating activities was $45.5 million, compared to $(2.8) million in the same period of 2024. Excluding $11.5 million of cash payments made in connection with the November 2024 restructuring, cash flow generated from operations was $57.0 million for the six months ended June 30, 2025. Cash Position As of June 30, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $315.1 million, compared to $358.5 million at December 31, 2024. For the six months ended June 30, 2025, the Company repurchased 11.2 million of its common shares for $90.8 million. The Board has approved an increase to the previously announced share repurchase plan of an additional $150 million of common shares. Purchases under the share repurchase plan, which to date have totaled 18.3 million of its common shares for $138.4 million, began on February 21, 2024. The expiry date of the share repurchase plan is not currently known. This program is being and will continue to be implemented through open market or privately negotiated purchases, including under a plan intended to benefit from the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by the Company based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any common shares will be determined in accordance with applicable U.S. securities laws. The Company is relying on the exemptive relief granted by the Canadian Securities Authorities as described in its February 29, 2024 press release. Full Year 2025 Total Revenue and Net Product Sales Guidance For 2025, Aurinia is increasing total revenue guidance from a range of $250 million to $260 million to a range of $260 million to $270 million and net product sales guidance from a range of $240 million to $250 million to a range of $250 million to $260 million. 'We continue to see solid growth for LUPKYNIS, partially driven by the new 2024 American College of Rheumatology lupus nephritis treatment guidelines, which recommend the incorporation of drugs like LUPKYNIS into first-line therapy in order to preserve kidney function,' stated Peter Greenleaf, President and Chief Executive Officer of Aurinia. 'Additionally, we are excited about the positive results from our Phase 1 study of aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Aritinercept was well tolerated at all dose levels tested and single doses led to robust and long-lasting reductions in immunoglobulins (antibodies). We look forward to initiating clinical studies in at least two autoimmune diseases in the second half of this year.' Webcast & Conference Call Details A webcast and conference call will be hosted today, July 31, at 8:30 a.m. ET. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia's most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) website at or the U.S. Securities and Exchange Commission's Electronic Document Gathering and Retrieval System (EDGAR) website at and on Aurinia's website at AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY (Unaudited) (in thousands, except per share data) Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024 Revenue Net product sales $ 66,574 $ 55,028 $ 126,545 $ 103,101 License, collaboration and royalty revenue 3,434 2,164 5,928 4,394 Total revenue 70,008 57,192 132,473 107,495 Operating expenses Cost of revenue 7,115 8,909 15,689 16,661 Selling, general and administrative 26,018 44,934 46,357 92,629 Research and development 7,432 4,080 13,175 9,631 Restructuring 114 1,072 1,647 7,755 Other expense (income), net 9,246 (290 ) 13,675 (4,415 ) Total operating expenses 49,925 58,705 90,543 122,261 Income (loss) from operations 20,083 (1,513 ) 41,930 (14,766 ) Interest income 3,190 4,189 6,759 8,715 Interest expense (1,117 ) (1,198 ) (2,184 ) (2,481 ) Net income (loss) before income taxes 22,156 1,478 46,505 (8,532 ) Income tax expense 643 756 1,648 1,495 Net income (loss) $ 21,513 $ 722 $ 44,857 $ (10,027 ) Earnings (loss) per share Basic $ 0.16 $ 0.01 $ 0.33 $ (0.07 ) Expand AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands) Six Months Ended June 30, 2025 2024 Cash flows from operating activities: Net income (loss) $ 44,857 $ (10,027 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Share-based compensation 2,031 14,323 Amortization and depreciation 9,720 9,690 Foreign exchange loss (gain) on revaluation of Monoplant finance lease liability 9,265 (5,705 ) Net amortization of premiums and discounts on investments (5,219 ) (6,331 ) Other, net 4,132 919 Net changes in operating assets and liabilities: Accounts receivable, net (3,547 ) (1,433 ) Inventory, net (7,275 ) 852 Prepaid expenses and other current assets 5,106 (4,305 ) Other noncurrent operating assets 730 (12 ) Accounts payable (1,875 ) 4,088 Accrued expenses and other liabilities (17,136 ) (3,805 ) Deferred revenue 5,147 (644 ) Lease liabilities (395 ) (365 ) Net cash provided by (used in) operating activities 45,541 (2,755 ) Cash flows from investing activities: Proceeds from the sale and maturities of investments 255,285 328,877 Purchases of investments (237,411 ) (318,126 ) Purchases of property, equipment and intangible assets (115 ) (140 ) Net cash provided by investing activities 17,759 10,611 Cash flows from financing activities: Repurchase of common shares (89,485 ) (18,435 ) Principal portion of finance lease payments (6,201 ) (6,001 ) Proceeds from issuance of common shares from exercise of stock options and vesting of RSUs and performance awards 10,590 6,134 Proceeds from issuance of common shares under ESPP 401 703 Taxes paid related to net settlement of exercises of stock options and vesting of RSUs and performance awards (9,036 ) (5,725 ) Net cash used in financing activities (93,731 ) (23,324 ) Net decrease in cash, cash equivalents and restricted cash (30,431 ) (15,468 ) Cash, cash equivalents and restricted cash, beginning of the period 83,433 48,875 Cash, cash equivalents and restricted cash, end of the period $ 53,002 $ 33,407 Expand
Yahoo
2 days ago
- Yahoo
MAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered Gastroenterology
Funding will support commercialization in the USA and Europe as well as continued development of MAGENTIQ COLO's advanced AI capabilities. HAIFA, Israel, July 30, 2025 /PRNewswire/ -- MAGENTIQ EYE LTD., a leading innovator in AI-powered gastroenterology decision-support software, today announced the successful completion of its Series A funding round. MAGENTIQ EYE's FDA- and CE-approved software, MAGENTIQ-COLO™, enhances polyp detection and analysis capabilities during colonoscopies, significantly improving adenoma detection rates. MAGENTIQ-COLO also offers real-time insights, and its CE-approved version includes polyp-size category and type estimation, and advanced AI-generated reports. The round was led by aMoon, Israel's largest HealthTech dedicated investment fund, joined by internal investors Norgine Ventures BV (Netherlands), Nina Capital (EU & USA) and Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA). In conjunction with aMoon's investment, partner Roy Wiesner will join the board of directors of MAGENTIQ EYE, bringing strategic insight, global perspective, and deep experience in building successful health tech companies. "This investment round marks a major milestone for MAGENTIQ EYE. We are thrilled to welcome aMoon and Roy Wiesner to our journey," said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE. "With aMoon's support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and Europe, and bring our advanced diagnostic tools to more physicians and patients around the world." "We are proud to partner with MAGENTIQ EYE, a company leading the charge in AI-powered colonoscopy," said Wiesner. "MAGENTIQ's solution stands out as the most accurate in the market, with the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications. We're also encouraged by the strong early commercial traction and the growing interest from major strategic players looking to collaborate. This investment reflects aMoon's commitment to backing transformative health tech solutions that can dramatically improve patient outcomes worldwide." The company is in clinical trials for diagnostic tools targeting specialized diseases in the lower and upper gastrointestinal tract, such as ulcerative colitis, early dysplasia in Barrett's esophagus, and gastric intestinal metaplasia, and is developing automated quality indicators for GI procedures. Proceeds from the funding round will support the continued development and expansion of these capabilities, in addition to driving commercial growth in the USA, Europe and globally through direct sales and MAGENTIQ EYE's existing and new partnerships with industry leaders. About MAGENTIQ-EYE in 2014, MAGENTIQ-EYE provides a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy and saving more and more lives. About aMoonaMoon is a global Healthtech & Life Sciences VC fund headquartered in Israel with $1.3B AUM. We partner with entrepreneurs harnessing groundbreaking science and technology to transform healthcare and help people live better, healthier lives. Backed by a team of scientists, physicians, and entrepreneurs, and a global network of investors and industry leaders, we connect portfolio companies to global tech, finance, and medical research hubs. Our Velocity Fund invests from venture formation through Series A, while our Growth Fund supports later-stage companies in growth, pre-IPO, or pivotal clinical rounds. Media contact:Kim MohrAmendola Communications on behalf of MAGENTIQ EYEkmohr@ View original content to download multimedia: SOURCE MAGENTIQ-EYE LTD. Sign in to access your portfolio
